Development of new drugs for COPD

Current Medicinal Chemistry

Volumn 20, Issue 12, 2013, Pages 1531-1540

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Anti inflammatory; Bronchodilator; Chemokine; Cytokine; Histone deacetylase; Janus kinase; Nuclear factor kB; P38 mitogen activated protein kinase; Phosphodiesterase 4; Phosphoinositide 3 kinase

Indexed keywords

ADZ 4818; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BRONCHODILATING AGENT; CLOFIBRATE; CORTICOSTEROID; FORMOTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDACATEROL; INFLIXIMAB; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; ROFLUMILAST; SALMETEROL; SETILEUTON; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; ZILEUTON;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG; NONHUMAN; SIGNAL TRANSDUCTION; STEM CELL; TISSUE REGENERATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84877949634     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320120005     Document Type: Article

References (94)

1. Barnes, P.J. Chronic obstructive pulmonary disease: A growing but neglected epidemic. PLoS Med., 2007, 4, e112.
2. Mannino, D.M.; Buist, A.S. Global burden of COPD: Risk factors, prevalence, and future trends. Lancet, 2007, 370, 765-773.
3. Barnes, P.J.; Shapiro, S.D.; Pauwels, R.A. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur. Respir. J., 2003, 22, 672-688.
4. Barnes, P.J. Emerging pharmacotherapies for COPD. Chest, 2008, 134, 1278-1286.
5. Barnes, P.J. Future treatments for COPD and its comorbidities. Proc. Am. Thorac. Soc., 2008, 5, 857-864.
6. Barnes, P.J.; Celli, B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J., 2009, 33, 1165-1185.
7. Barnes, P.J. Theophylline for COPD. Thorax, 2006, 61: 742-743.
8. Barnes, P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Immunol. Rev., 2008, 8, 183-192.
9. Makita, H.; Nasuhara, Y.; Nagai, K.; Ito, Y.; Hasegawa, M.; Betsuyaku, T.; Onodera, Y.; Hizawa, N.; Nishimura, M. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax, 2007, 62, 932-937.
10. Sturton, G.; Persson, C.; Barnes, P.J. Small airways: An important but neglected target in the treatment of obstructive airway diseases. Trends. Phamacol. Sci., 2008, 29, 340-345.
11. van den, B.M.; ten Hacken, N.H.; Cohen, J.; Douma, W.R.; Postma, D.S. Small airway disease in asthma and COPD: Clinical implications. Chest, 2011, 139, 412-423.
12. Calverley, P.M.; Anderson, J.A.; Celli, B.; Ferguson, G.T.; Jenkins, C.; Jones, P.W.; Yates, J.C.; Vestbo, J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med., 2007, 356, 775-789.
13. Cazzola, M.; Macnee, W.; Martinez, F.J.; Rabe, K.F.; Franciosi, L.G.; Barnes, P.J.; Brusasco, V.; Burge, P.S.; Calverley, P.M.; Celli, B.R.; Jones, P.W.; Mahler, D.A.; Make, B.; Miravitlles, M.; Page, C.P.; Palange, P.; Parr, D.; Pistolesi, M.; Rennard, S.I. et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur. Respir. J., 2008, 31, 416-469.
14. Han, M.K.; Agusti, A.; Calverley, P.M.; Celli, B.R.; Criner, G.; Curtis, J.L.; Fabbri, L.M.; Goldin, J.G.; Jones, P.W.; Macnee, W.; Make, B.J.; Rabe, K.F.; Rennard, S.I.; Sciurba, F.C.; Silverman, E.K.; Vestbo, J.; Washko, G.R.; Wouters, E.F.; Martinez, F.J. Chronic obstructive pulmonary disease phenotypes: The future of COPD. Am. J. Respir. Crit. Care Med., 2010, 182, 598-604.
15. Barnes, P.J.; Chowdhury, B.; Kharitonov, S.A.; Magnussen, H.; Page, C.P.; Postma, D.; Saetta, M. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2006, 174, 6-14.
16. Rabe, K.F.; Hurd, S.; Anzueto, A.; Barnes, P.J.; Buist, S.A.; Calverley, P.; Fukuchi, Y.; Jenkins, C.; Rodriguez-Roisin, R.; van Weel, C.; Zielinski, J. Global strategy for the diagnosis, management, and prevention of COPD-2006 Update. Am. J. Respir. Crit. Care Med., 2007, 176, 532-555.
17. Vogelmeier, C.; Magnussen, H.; Laforce, C.; Owen, R.; Kramer, B. Profiling the bronchodilator effects of the novel ultra-long-acting {beta}2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease. Ther. Adv. Respir. Dis., 2011.
18. Sturton, R.G.; Nicholson, A.G.; Trifilieff, A.; Barnes, P.J. Pharmacological characterisation of indacaterol, a novel once-daily inhaled b2-adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J. Pharmacol. Exp. Ther., 2008, 324, 270-275.
19. Rennard, S.; Bantje, T.; Centanni, S.; Chanez, P.; Chuchalin, A.; D'Urzo, A.; Kornmann, O.; Perry, S.; Jack, D.; Owen, R.; Higgins, M. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir. Med., 2008, 102, 1033-1044.
20. Cazzola, M.; Calzetta, L.; Matera, M.G. beta(2)-adrenoceptor agonists: Current and future direction. Br. J. Pharmacol., 2011, 163, 4-17.
21. Cazzola, M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr. Opin. Investig. Drugs, 2009, 10, 482-490.
22. van Noord, J.A.; Buhl, R.; Laforce, C.; Martin, C.; Jones, F.; Dolker, M.; Overend, T. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax, 2010, 65, 1086-1091.
23. Ray, N.C.; Alcaraz, L. Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: A patent review. Expert Opin. Ther. Pat., 2009, 19, 1-12.
24. Barnes, P.J. Triple inhalers for obstructive airways disease: Will they be useful? Expert Rev. Respir. Med., 2011, 5, 297-300.
25. Aaron, S.D.; Vandemheen, K.L.; Fergusson, D.; Maltais, F.; Bourbeau, J.; Goldstein, R.; Balter, M.; O'Donnell, D.; McIvor, A.; Sharma, S.; Bishop, G.; Anthony, J.; Cowie, R.; Field, S.; Hirsch, A.; Hernandez, P.; Rivington, R.; Road, J.; Hoffstein, V. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann. Intern. Med., 2007, 146, 545-555.
26. Deshpande, D.A.; Wang, W.C.; McIlmoyle, E.L.; Robinett, K.S.; Schillinger, R.M.; An, S.S.; Sham, J.S.; Liggett, S.B. Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction. Nat. Med., 2010, 16, 1299-1304.
27. Hays, J.T.; Ebbert, J.O. Varenicline for tobacco dependence. N. Engl. J. Med., 2008, 359, 2018-2024.
28. Siu, E.C.; Tyndale, R.F. Non-nicotinic therapies for smoking cessation. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 541-564.
29. Barnes, P.J. Mediators of chronic obstructive pulmonary disease. Pharm. Rev., 2004, 56, 515-548.
30. Barnes, P.J. Cytokine networks in asthma and chronic obstructive pulmonary disease. J. Clin. Invest., 2008, 118, 3546-3556.
31. Barnes, P.J. The cytokine network in COPD. Am. J. Respir. Cell Mol. Biol., 2009, 41, 631-638.
32. Hicks, A.; Monkarsh, S.P.; Hoffman, A.F.; Goodnow, R., Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: Preclinical and clinical developments. Expert Opin. Investig. Drugs, 2007, 16, 1909-1920.
33. Bernstein, J.A.; Liu, N.; Knorr, B.A.; Smugar, S.S.; Hanley, W.D.; Reiss, T.F.; Greenberg, S. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease. Respir. Med., 2011, 105, 392-401.
34. Woodruff, P.G.; Albert, R.K.; Bailey, W.C.; Casaburi, R.; Connett, J.E.; Cooper, J.A., Jr.; Criner, G.J.; Curtis, J.L.; Dransfield, M.T.; Han, M.K.; Harnden, S.M.; Kim, V.; Marchetti, N.; Martinez, F.J.; McEvoy, C.E.; Niewoehner, D.E.; Reilly, J.J.; Rice, K.; Scanlon, P.D. et al. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD, 2011, 8, 21-29.
35. Rennard, S.I.; Fogarty, C.; Kelsen, S.; Long, W.; Ramsdell, J.; Allison, J.; Mahler, D.; Saadeh, C.; Siler, T.; Snell, P.; Korenblat, P.; Smith, W.; Kaye, M.; Mandel, M.; Andrews, C.; Prabhu, R.; Donohoue, J.F.; Watt, R.; Hung, K.L. et al. The safety and efficacy of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2007, 175, 926-934.
36. Paul-Pletzer, K. Tocilizumab: Blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today (Barc.), 2006, 42, 559-576.
37. Donnelly, L.E.; Barnes, P.J. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol. Sci., 2006, 27, 546-553.
38. Mahler, D.A.; Huang, S.; Tabrizi, M.; Bell, G.M. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: A pilot study. Chest, 2004, 126, 926-934.
39. Donnelly, L.E.; Barnes, P.J. CXCR2 antagonism to prevent airway inflammation. Drugs Future, 2011.
40. O'Connor, B.J.; Leaker, B.R.; Barnes, P.J.; Nicholson, G.; Grahames, C.; Larsson, B.; Gaw, A.; Snell, N.; Newbold, P. Inhibition of LPS-induced neutrophilic inflammation in healthy volunteers. Eur. Resp. J., 2007, 30 (Suppl 51): 1294.
41. Holz, O.; Khalilieh, S.; Ludwig-Sengpiel, A.; Watz, H.; Stryszak, P.; Soni, P.; Tsai, M.; Sadeh, J.; Magnussen, H. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur. Respir. J., 2010, 35, 564-570.
42. Magnussen, H.; Watz, H.; Sauer, M.; Khanskaya, I.; Gann, L.; Stryszak, P.; Staudiger, H.; Sadeh, H. Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD. Eur. Resp. J., 2010, 36(suppl): 38S.
43. Costa, C.; Rufino, R.; Traves, S.L.; Lapa E Silva JR; Barnes, P.J.; Donnelly, L.E. CXCR3 and CCR5 chemokines in the induced sputum from patients with COPD. Chest, 2008, 133, 26-33.
44. Kerstjens, H.A.; Bjermer, L.; Eriksson, L.; Dahlstrom, K.; Vestbo, J. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients. Respir. Med., 2010, 104, 1297-1303.
45. Koli, K.; Myllarniemi, M.; Keski-Oja, J.; Kinnula, V.L. Transforming growth factor-beta activation in the lung: Focus on fibrosis and reactive oxygen species. Antioxid. Redox. Signal., 2008, 10: 333-342.
46. Wang, I.M.; Stepaniants, S.; Boie, Y.; Mortimer, J.R.; Kennedy, B.; Elliott, M.; Hayashi, S.; Loy, L.; Coulter, S.; Cervino, S.; Harris, J.; Thornton, M.; Raubertas, R.; Roberts, C.; Hogg, J.C.; Crackower, M.; O'Neill, G.; Pare, P.D. Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am. J. Respir. Crit. Care Med., 2008, 177, 402-411.
47. Leung, S.Y.; Niimi, A.; Noble, A.; Oates, T.; Williams, A.S.; Medicherla, S.; Protter, A.A.; Chung, K.F. Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling. J. Pharmacol. Exp. Ther., 2006, 319, 586-594.
48. Groutas, W.C.; Dou, D.; Alliston, K.R. Neutrophil elastase inhibitors. Expert. Opin. Ther. Pat., 2011.
49. Hu, J.; Van Den Steen, P.E.; Sang, Q.X.; Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov., 2007, 6, 480-498.
50. Churg, A.; Wang, R.; Wang, X.; Onnervik, P.O.; Thim, K.; Wright, J.L. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax, 2007, 62, 706-713.
51. Li, W.; Li, J.; Wu, Y.; Wu, J.; Hotchandani, R.; Cunningham, K.; McFadyen, I.; Bard, J.; Morgan, P.; Schlerman, F.; Xu, X.; Tam, S.; Goldman, S.J.; Williams, C.; Sypek, J.; Mansour, T.S. A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): Discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3- sulfonamido)-3-methylbutanoic acid (MMP408). J. Med. Chem., 2009, 52, 1799-1802.
52. Barnes, P.J.; Adcock, I.M. Glucocorticoid resistance in inflammatory diseases. Lancet, 2009, 342, 1905-1917.
53. Suissa, S.; Barnes, P.J. Inhaled corticosteroids in COPD: The case against. Eur. Respir. J., 2009, 34, 13-16.
54. Barnes, P.J. Inhaled corticosteroids in COPD: A controversy. Respiration, 2010, 80, 89-95.
55. Diamant, Z.; Spina, D. PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease. Pulm. Pharmacol. Ther., 2011, 24, 353-360.
56. Hatzelmann, A.; Morcillo, E.J.; Lungarella, G.; Adnot, S.; Sanjar, S.; Beume, R.; Schudt, C.; Tenor, H. The preclinical pharmacology of roflumilast-A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther., 2010, 23, 235-256.
57. Grootendorst, D.C.; Gauw, S.A.; Verhoosel, R.M.; Sterk, P.J.; Hospers, J.J.; Bredenbroker, D.; Bethke, T.D.; Hiemstra, P.S.; Rabe, K.F. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax, 2007, 62, 1081-1087.
58. Calverley, P.M.; Rabe, K.F.; Goehring, U.M.; Kristiansen, S.; Fabbri, L.M.; Martinez, F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials. Lancet, 2009, 374, 685-694.
59. Fabbri, L.M.; Calverley, P.M.; Izquierdo-Alonso, J.L.; Bundschuh, D.S.; Brose, M.; Martinez, F.J.; Rabe, K.F. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: Two randomised clinical trials. Lancet, 2009, 374, 695-703.
60. Smith, S.J.; Cieslinski, L.B.; Newton, R.; Donnelly, L.E.; Fenwick, P.S.; Nicholson, A.G.; Barnes, P.J.; Barnette, M.S.; Giembycz, M.A. Discovery of BRL 50481, a selective inhibitor of phosphodiesterase 7: In vitro studies in human monocytes, lung macrophages and CD8+ T-lymphocytes. Mol. Pharmacol., 2004, 66, 1679-1689.
61. Giembycz, M.A. Phosphodiesterase-4: Selective and dualspecificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc., 2005, 2, 326-333.
62. Banner, K.H.; Press, N.J. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br. J. Pharmacol., 2009, 157, 892-906.
63. Birrell, M.A.; Wong, S.; Hardaker, E.L.; Catley, M.C.; McCluskie, K.; Collins, M.; Haj-Yahia, S.; Belvisi, M.G. IkappaB kinase-2-independent and-dependent inflammation in airway disease models: Relevance of IKK-2 inhibition to the clinic. Mol. Pharmacol., 2006, 69, 1791-1800.
64. Renda, T.; Baraldo, S.; Pelaia, G.; Bazzan, E.; Turato, G.; Papi, A.; Maestrelli, P.; Maselli, R.; Vatrella, A.; Fabbri, L.M.; Zuin, R.; Marsico, S.A.; Saetta, M. Increased activation of p38 MAPK in COPD. Eur. Respir. J., 2008, 31, 62-69.
65. Smith, S.J.; Fenwick, P.S.; Nicholson, A.G.; Kirschenbaum, F.; Finney-Hayward, T.K.; Higgins, L.S.; Giembycz, M.A.; Barnes, P.J.; Donnelly, L.E. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br. J. Pharmacol., 2006, 149, 393-404.
66. Medicherla, S.; Fitzgerald, M.; Spicer, D.; Woodman, P.; Ma, J.Y.; Kapoun, A.M.; Chakravarty, S.; Dugar, S.; Protter, A.A.; Higgins, L.S. p38a selective MAP kinase inhibitor, SD-282, reduces inflammation in a sub-chronic model of tobacco smoke-induced airway inflammation. J. Pharmacol. Exp. Ther., 2007, 324, 921-929.
67. Lomas, D.A.; Lipson, D.A.; Miller, B.E.; Willits, L.; Keene, O.; Barnacle, H.; Barnes, N.C.; Tal-Singer, R. An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease. J. Clin. Pharmacol., 2011.
68. Tudhope, S.J.; Finney-Hayward, T.K.; Nicholson, A.G.; Mayer, R.J.; Barnette, M.S.; Barnes, P.J.; Donnelly, L.E. Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage. J. Pharmacol. Exp. Ther., 2008, 324, 306-312.
69. Medina-Tato, D.A.; Ward, S.G.; Watson, M.L. Phosphoinositide 3-kinase signalling in lung disease: Leucocytes and beyond. Immunology, 2007, 121, 448-461.
70. Marwick, J.A.; Caramori, G.; Stevenson, C.C.; Casolari, P.; Jazrawi, E.; Barnes, P.J.; Ito, K.; Adcock, I.M.; Kirkham, P.A.; Papi, A. Inhibition of PI3Kd restores glucocorticoid function in smoking-induced airway inflammation in mice. Am. J. Respir. Crit. Care Med., 2009, 179, 542-548.
71. To, Y.; Ito, K.; Kizawa, Y.; Failla, M.; Ito, M.; Kusama, T.; Elliot, M.; Hogg, J.C.; Adcock, I.M.; Barnes, P.J. Targeting phosphoinositide-3-kinase-d with theophylline reverses corticosteroid insensitivity in COPD. Am. J. Resp. Crit. Care Med., 2010, 182, 897-904.
72. Di Stefano, A.; Caramori, G.; Capelli, A.; Gnemmi, I.; Ricciardolo, F.; Oates, T.; Donner, C.F.; Chung, K.F.; Barnes, P.J.; Adcock, I.M. STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur. Resp. J., 2004, 24, 78-85.
73. Qu, P.; Roberts, J.; Li, Y.; Albrecht, M.; Cummings, O.W.; Eble, J.N.; Du, H.; Yan, C. Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. Lung Cancer, 2009, 63, 341-347.
74. Coombs, J.H.; Bloom, B.J.; Breedveld, F.C.; Fletcher, M.P.; Gruben, D.; Kremer, J.M.; Burgos-Vargas, R.; Wilkinson, B.; Zerbini, C.A.; Zwillich, S.H. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: Results from a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis., 2010, 69, 413-416.
75. Belvisi, M.G.; Hele, D.J.; Birrell, M.A. Peroxisome proliferatoractivated receptor gamma agonists as therapy for chronic airway inflammation. Eur. J. Pharmacol., 2006, 533, 101-109.
76. Milam, J.E.; Keshamouni, V.G.; Phan, S.H.; Hu, B.; Gangireddy, S.R.; Hogaboam, C.M.; Standiford, T.J.; Thannickal, V.J.; Reddy, R.C. PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol., 2008, 294, L891-L901.
77. Remels, A.H.; Schrauwen, P.; Broekhuizen, R.; Willems, J.; Kersten, S.; Gosker, H.R.; Schols, A.M. Peroxisome proliferatoractivated receptor expression is reduced in skeletal muscle in COPD. Eur. Respir. J., 2007, 30, 245-252.
78. Yang, I.A.; Fong, K.M.; Sim, E.H.; Black, P.N.; Lasserson, T.J. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev., 2007, CD002991.
79. Barnes, P.J. Role of HDAC2 in the pathophysiology of COPD. Ann. Rev. Physiol., 2009, 71, 451-464.
80. Ito, K.; Yamamura, S.; Essilfie-Quaye, S.; Cosio, B.; Ito, M.; Barnes, P.J.; Adcock, I.M. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kB suppression. J. Exp. Med., 2006, 203, 7-13.
81. Ford, P.A.; Durham, A.L.; Russell, R.E.K.; Gordon, F.; Adcock, I.M.; Barnes, P.J. Treatment effects of low dose theophylline combined with an inhaled corticosteroid in COPD. Chest, 2010, 137, 1338-1344.
82. Mercado, N.; To, Y.; Ito, K.; Barnes, P.J. Nortriptyline reverses corticosteroid insensitivity by inhibition of PI3K-d. J. Pharmacol. Exp. Ther., 2011, 337, 465-470.
83. Kirkham, P.; Rahman, I. Oxidative stress in asthma and COPD: Antioxidants as a therapeutic strategy. Pharmacol. Ther., 2006, 111, 476-494.
84. Malhotra, D.; Thimmulappa, R.; Navas-Acien, A.; Sandford, A.; Elliott, M.; Singh, A.; Chen, L.; Zhuang, X.; Hogg, J.; Pare, P.; Tuder, R.M.; Biswal, S. Decline in NRF2 regulated antioxidants in COPD lungs due to loss of its positive regulator DJ-1. Am. J. Respir. Crit. Care Med., 2008, 178, 592-604.
85. Mercado, N.; Thimmulappa, R.; Thomas, C.M.; Fenwick, P.S.; Chana, K.K.; Donnelly, L.E.; Biswal, S.; Ito, K.; Barnes, P.J. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem. Biophys. Res. Commun., 2011, 406, 292-298.
86. Sussan, T.E.; Rangasamy, T.; Blake, D.J.; Malhotra, D.; El Haddad, H.; Bedja, D.; Yates, M.S.; Kombairaju, P.; Yamamoto, M.; Liby, K.T.; Sporn, M.B.; Gabrielson, K.L.; Champion, H.C.; Tuder, R.M.; Kensler, T.W.; Biswal, S. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc. Natl. Acad. Sci. USA, 2009, 106, 250-255.
87. Seemungal, T.A.; Wilkinson, T.M.; Hurst, J.R.; Perera, W.R.; Sapsford, R.J.; Wedzicha, J.A. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med., 2008, 178, 1139-1147.
88. Albert, R.K.; Connett, J.; Bailey, W.C.; Casaburi, R.; Cooper, J.A., Jr.; Criner, G.J.; Curtis, J.L.; Dransfield, M.T.; Han, M.K.; Lazarus, S.C.; Make, B.; Marchetti, N.; Martinez, F.J.; Madinger, N.E.; McEvoy, C.; Niewoehner, D.E.; Porsasz, J.; Price, C.S.; Reilly, J. et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med., 2011, 365, 689-698.
89. Altenburg, J.; de GRAAFF, C.S.; van der Werf, T.S.; Boersma, W.G. Immunomodulatory effects of macrolide antibiotics-part 1: Biological mechanisms. Respiration, 2011, 81, 67-74.
90. Charron, C.; Sumakuza, T.; Oomura, S.; Ito, K. EM-703, a nonantibacterial erythromycin derivative, restores HDAC2 activition diminished by hypoxia and oxidative stress. Proc. Am. Thorac. Soc., 2007, 175, A640.
91. Roth, M.D.; Connett, J.E.; D'Armiento, J.M.; Foronjy, R.F.; Friedman, P.J.; Goldin, J.G.; Louis, T.A.; Mao, J.T.; Muindi, J.R.; O'Connor, G.T.; Ramsdell, J.W.; Ries, A.L.; Scharf, S.M.; Schluger, N.W.; Sciurba, F.C.; Skeans, M.A.; Walter, R.E.; Wendt, C.H.; Wise, R.A. Feasibility of retinoids for the treatment of emphysema study. Chest, 2006, 130, 1334-1345.
92. Hind, M.; Maden, M. Is a regenerative approach viable for the treatment of COPD? Br. J. Pharmacol., 2011, 163, 106-115.
93. Ott, H.C.; Clippinger, B.; Conrad, C.; Schuetz, C.; Pomerantseva, I.; Ikonomou, L.; Kotton, D.; Vacanti, J.P. Regeneration and orthotopic transplantation of a bioartificial lung. Nat. Med., 2010, 16, 927-933.
94. Salvi, S.S.; Barnes, P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet, 2009, 374, 733-743.